RMTI director John G. Cooper reports 5,079-share stock sale

Rhea-AI Filing Summary

Rockwell Medical, Inc. (RMTI) director John G. Cooper reported an open-market sale of company stock. On November 18, 2025, he sold 5,079 shares of Rockwell Medical common stock at a price of $0.87 per share, according to this Form 4 filing. After this transaction, Cooper beneficially owns 140,372 shares of Rockwell Medical common stock, held directly.

Insider Trade Summary

Net Seller: 5,079 shares

Net Sell 1 txn

Insider COOPER JOHN G

Role Director

Sold 5,079 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,079	$0.87	$4K

Holdings After Transaction: Common Stock — 140,372 shares (Direct)

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/18/2025 - 04:26 PM Learn about SEC filing dates

FAQ

What insider transaction did Rockwell Medical (RMTI) report in this Form 4?

The filing reports that director John G. Cooper sold 5,079 shares of Rockwell Medical common stock on November 18, 2025 at a price of $0.87 per share.

How many Rockwell Medical (RMTI) shares does the insider hold after the sale?

Following the reported transaction, John G. Cooper beneficially owns 140,372 shares of Rockwell Medical common stock, reported as held directly.

What is the role of the reporting person in Rockwell Medical (RMTI)?

The reporting person, John G. Cooper, is identified as a Director of Rockwell Medical, Inc. in the Form 4.

What type of security was sold in this Rockwell Medical (RMTI) Form 4 filing?

The transaction involved the sale of common stock of Rockwell Medical, Inc., as shown in Table I of the Form 4.

Was any derivative security activity reported for Rockwell Medical (RMTI)?

Table II of the Form 4, which covers derivative securities such as options or warrants, does not list any derivative transactions in the provided content.

What does a Form 4 filing for Rockwell Medical (RMTI) indicate to investors?

A Form 4 shows recent trades in Rockwell Medical securities by company insiders, such as directors, and discloses the date, number of shares, price, and resulting holdings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COOPER JOHN G

(Last) (First) (Middle)

C/O ROCKWELL MEDICAL, INC.

30142 WIXOM ROAD

(Street)

WIXOM MI 48393

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ROCKWELL MEDICAL, INC. [ RMTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/18/2025		S		5,079	D	$0.87	140,372	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Megan Timmins, Attorney-in-Fact for John G. Cooper	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.